Plenaire lezing

 

Naam: Drs. Hans G.C.P. Schikan

Hans Schikan brings more than 25 years of development, commercial and leadership experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases, with a lead program in Duchenne Muscular Dystrophy. During his leadership, Prosensa entered into a collaboration with GlaxoSmithKline, was listed on NASDAQ with a successful IPO in 2013 and was acquired by BioMarin early 2015 for up to USD 840 million. His previous assignments include leadership roles at Genzyme (acquired by Sanofi) and Organon (acquired by Schering Plough). He currently serves on the board of a number of biotech companies (public and private) in The Netherlands, Belgium, Sweden, Switzerland and the United Kingdom, partly as chairman of the board. 

He is also member of the core team of the Dutch Top Sector for Life Sciences and Health. Hans is chairman of the Investor Board of Swanbridge Capital and co-founder/board member of Pharvaris.

Finally, he was appointed Special Envoy for vaccines by the Dutch Minister of Health, to explore further optimization in the production and scale-up of vaccines for COVID-19.

Hans studied pharmacy in Utrecht where he received his PharmD degree.